Use of H3K9me3 modulation for enhancing cognitive function

Patent metadata

Field	Value
Publication number	US-10272093-B2
Application number	US-201615580419-A
Country	US
Kind code	B2
Filing date	Jun 3, 2016
Priority date	Jun 8, 2015
Publication date	Apr 30, 2019
Grant date	Apr 30, 2019

Abstract

Use of H3K9me3 modulation for enhancing cognitive function and treating anxiety related disorders is presented. A composition is administered to the subject comprising a therapeutically effective amount of a SUV39H1 inhibitor comprising analogs of ETP69. The therapeutically effective amount is effective in treating cognitive dysfunction in aging and age-related disorders.

First claim

What is claimed is:

1. A method of reversing cognition loss in an animal subject in need thereof, the method comprising:
selecting an animal subject with cognitive loss; and
administering a therapeutically effective amount of a SUV39H1 inhibitor compound to said animal subject, wherein said therapeutically effective amount comprises single dosing for acute treatment and repeated dosing for chronic treatment.

2. A method of reversing cognition loss in a patient in need thereof, the method comprising:
selecting a patient with loss of memory function; and
administering to the patient a therapeutically effective amount of a SUV39H1 inhibitor compound together with a pharmaceutical cognitive enhancer, wherein said therapeutically effective amount comprises single dosing for acute treatment and repeated dosing for chronic treatment.

3. The method of claim 2 , wherein the cognitive enhancer is a cholinesterase inhibitor.

4. The method of claim 3 , wherein the cholinesterase inhibitor is selected from a group comprising tacrine, donepezil, rivastigmine, and galantamine.

5. The method of claim 2 , wherein the cognitive enhancer is an NMDA antagonist or an NMDA agonist.

6. The method of claim 2 , wherein the cognitive enhancer is an ampakine.

7. The method of claim 2 , wherein the cognitive enhancer is a BZD/GABA receptor complex modulator.

8. The method of claim 2 , wherein the cognitive enhancer is a serotonin antagonist.

9. The method of claim 2 , wherein the cognitive enhancer is a nicotinic class compound.

10. The method of claim 2 , wherein the cognitive enhancer is a muscarinic class compound.

11. The method of claim 2 , wherein the cognitive enhancer is a PDE inhibitor.

12. The method of claim 2 , wherein the cognitive enhancer is a G protein class compound.

13. The method of claim 2 , wherein the cognitive enhancer is a channel modulator.

14. The method of claim 2 , wherein the cognitive enhancer is an immunotherapeutic class compound.

15. The method of claim 2 , wherein the cognitive enhancer is an anti-amyloid or amyloid lowering agent.

16. The method of claim 2 , wherein the cognitive enhancer is a statin or a PPARS modulator.

17. A method of enhancing cognition in a subject in need thereof, the method comprising:
selecting a subject in need of memory enhancement; and
administering to the subject a therapeutically effective amount of a SUV39H1 inhibitor compound together with a lifestyle cognitive enhancer.

18. The method of claim 17 , wherein the cognitive enhancer is physical exercise.

19. The method of claim 17 , wherein the cognitive enhancer is mental exercise.

20. The method of claim 17 , wherein the cognitive enhancer is dietary supplement.

21. The method of claim 20 , wherein the supplement is an antioxidant.

22. The method of claim 20 , wherein the supplement is a mitochondrial function enhancer.

23. The method of claim 20 , wherein the supplement is caffeine.

24. The method of claim 20 , wherein the supplement is omega-3.

25. The method of claim 20 , wherein the supplement is Docosahexaenoic acid (DHA).

26. A method of treatment, prevention or alleviation of a cognitive dysfunction of a living animal subject, including a human, the method comprising:
selecting a living animal subject with signs of cognitive loss; and
administering to such living animal subject a therapeutically effective amount of a SUV39H1 inhibitor compound.

27. A method of treatment for extinction of conditioned fear in an animal subject, the method comprising:
selecting an animal subject with conditioned fear behavior; and
administering a therapeutically effective amount of a SUV39H1 inhibitor compound to said animal subject, wherein said therapeutically effective amount comprises single dosing for acute treatment and repeated dosing for chronic treatment.

Assignees

• Univ California

Inventors

• Cotman Carl W
• Overman Larry E
• Snigdha Shikha

Classifications

• A61K31/27

  of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine · CPC title

• A61K31/473

  ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines · CPC title

• A61K31/445

  Non condensed piperidines, e.g. piperocaine · CPC title

• A61K31/548 Primary

  having two or more sulfur atoms in the same ring · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title